Barry Ticho Sells 7,176 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

August 6, 2026 by InsiderTrades.com

Key Points

Insider sale: Barry Ticho sold 7,176 Stoke Therapeutics shares for approximately $208,000 under a pre-arranged Rule 10b5-1 plan, reducing his direct stake by 26% to 20,422 shares.
Quarterly results: Stoke reported a second-quarter loss of $0.93 per share, missing the $0.80 consensus estimate, while revenue of about $9.32 million exceeded expectations.
Analyst outlook: The stock carries a “Moderate Buy” consensus rating from analysts, with an average price target of $43 versus recent trading near $31.93, although ratings and targets remain mixed.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 7,176 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $29.04, for a total value of $208,391.04. Following the sale, the insider directly owned 20,422 shares of the company's stock, valued at approximately $593,054.88. This trade represents a 26.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10.

Stoke Therapeutics Stock Up 0.8%

Shares of NASDAQ STOK opened at $31.93 on Thursday. The firm's fifty day moving average is $30.41 and its 200 day moving average is $32.03. Stoke Therapeutics, Inc. has a 52 week low of $12.75 and a 52 week high of $40.22. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -9.56 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to analysts' expectations of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. Equities research analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Hussman Strategic Advisors Inc. bought a new position in Stoke Therapeutics in the fourth quarter worth about $2,000,000. Baillie Gifford & Co. bought a new stake in Stoke Therapeutics during the 4th quarter valued at approximately $7,837,000. Dimensional Fund Advisors LP boosted its position in Stoke Therapeutics by 19.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company's stock valued at $32,229,000 after acquiring an additional 162,797 shares in the last quarter. Janus Henderson Group PLC boosted its position in Stoke Therapeutics by 11.2% during the 1st quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company's stock valued at $52,456,000 after acquiring an additional 161,848 shares in the last quarter. Finally, Candriam S.C.A. grew its holdings in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Candriam S.C.A. now owns 502,020 shares of the company's stock worth $16,346,000 after acquiring an additional 55,330 shares during the period.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. BTIG Research reiterated a "buy" rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Weiss Ratings downgraded Stoke Therapeutics from a "hold (c)" rating to a "sell (d)" rating in a report on Monday, May 11th. Canaccord Genuity Group lowered their price target on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a research report on Tuesday. Chardan Capital reiterated a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. Finally, Wedbush increased their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an "outperform" rating in a report on Tuesday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $43.00.

Get Our Latest Stock Analysis on Stoke Therapeutics

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

Positive Sentiment: Guggenheim reaffirmed its “buy” rating and set a $60 price target, while Wedbush raised its target to $40 and maintained an “outperform” rating. Chardan also reiterated “buy,” and Canaccord maintained “buy” despite trimming its target to $58. The targets imply substantial upside from recent trading levels. Analyst rating and price-target updates
Positive Sentiment: Management’s second-quarter update highlighted plans to submit a rolling NDA for zorevunersen in the first quarter of 2027, supporting a potential U.S. launch by early 2028. The company also reported approximately $420 million in cash, which could fund development and launch preparation. Stoke outlines rolling NDA and cash position
Positive Sentiment: A bullish research commentary cited the potential for the zorevunersen NDA in SCN1A-related Dravet syndrome and continued advancement of STK-002, reinforcing the company’s pipeline-driven investment case. Stoke buy thesis on zorevunersen and STK-002
Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, providing an opportunity for management to discuss its clinical and regulatory plans with investors. Stoke Therapeutics conference presentation
Negative Sentiment: Stoke reported a second-quarter loss of $0.93 per share versus the $0.80 consensus estimate, although revenue of $9.33 million exceeded expectations. HC Wainwright subsequently reduced its FY2029 EPS estimate to $1.55 from $1.63 and its FY2030 estimate to $3.56 from $3.74. Stoke Therapeutics Q2 2026 earnings call summary
Negative Sentiment: Director Barry Ticho sold 7,176 shares worth approximately $208,000, reducing his direct stake by 26%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its negative significance but may still weigh modestly on sentiment. SEC insider sale filing

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.